Rituxan Pronunciation
Generic Name: rituximab (ri TUX i mab)
Brand Names: Rituxan
RITUXANŽ (rituximab) is indicated for the treatment of:
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy Low-grade CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who did not progress on initial treatment with CVP chemotherapy CD20-positive diffuse large B-cell non-Hodgkin's lymphoma as an initial treatment in combination with CHOP chemotherapy CD20-positive chronic lymphocytic leukemia in combination with FC chemotherapy as an initial treatment or as a treatment after disease has recurred Rheumatoid arthritis with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA in adults, after treatment with at least one other medicine called tumor necrosis factor (TNF) antagonist has been used and did not work well enough Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) with glucocorticoids
People with serious infections should not receive RITUXAN. It is not known if RITUXAN is safe or effective in children.
Last edited by drz; 09-03-2016 at 10:50 AM.
Knowledge is power! Wisdom is using it to make good decisions!
Bookmarks